SummaryThis study is recruiting people who have verified gastrointestinal stromal tumour (GIST) with a high risk of recurrence, despite removal of all macroscopic GIST tissue during surgery and having received 3 years of adjuvant imatinib. Study participants will be randomly allocated to either Arm A or Arm B. In Arm A (Experimental), participants will continue receiving imatinib (400mg/day for 24 months). In Arm B, participants will stop receiving imatinib. All participants will be followed up using blood tests and scans of the abdomen.
This trial is treating patients with gastrointestinal stromal tumours.
18 - 100
Use the hyperlinks, where available to access additional clinical trial information.
Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST With a High Risk for Recurrence: A Randomised Phase III Study